# Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

> **NCT07162038** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 155 (estimated)

## Conditions studied

- Hematologic Malignancies
- Hematologic Neoplasms

## Interventions

- **BIOLOGICAL:** mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL)
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Sirolimus
- **DEVICE:** CD19 Flow Cytometry Assay
- **DEVICE:** CD19 Immunohistochemical Assay
- **RADIATION:** Total Body Irradiation

## Key facts

- **NCT ID:** NCT07162038
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-14
- **Primary completion:** 2030-11-01
- **Final completion:** 2034-10-01
- **Target enrollment:** 155 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07162038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07162038, "Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT07162038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*